Stock ROG ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Roche Holding AG

Equities

ROG

CH0012032048

Market Closed - Swiss Exchange
Other stock markets
 11:31:13 2024-05-23 am EDT 		5-day change 1st Jan Change
232.1 CHF +0.09% Intraday chart for Roche Holding AG -1.15% -5.07%
May. 22 Roche: FDA designation for blood test CF
May. 22 Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT

Summary

  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • With an enterprise value anticipated at 3.31 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 205B
A+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+39.51% 723B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.28% 595B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.65% 369B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.35% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+2.88% 282B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.15% 244B
B+
NOVARTIS AG Stock Novartis AG
+9.31% 208B
B-
PFIZER, INC. Stock Pfizer, Inc.
-0.02% 168B
C+
AMGEN INC. Stock Amgen Inc.
+7.21% 166B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. Ratings Roche Holding AG